Page 107 - 2023-06-中国全科医学

·748· http: //www.chinagp.net E-mail: zgqkyx@chinagp.net.cn February 2023, Vol.26 No.6

disease［J］. BMC Gastroenterol，2021，21（1）：144. DOI： ［55］VRIEZE A，VAN NOOD E，HOLLEMAN F，et al. Transfer of
10.1186/s12876-021-01660-5. intestinal microbiota from lean donors increases insulin sensitivity
［44］KOBYLIAK N，ABENAVOLI L，MYKHALCHYSHYN G，et al. in individuals with metabolic syndrome［J］. Gastroenterology，
A multi-strain probiotic reduces the fatty liver index，cytokines 2012，143（4）：913-916.e7. DOI：10.1053/ j.
and aminotransferase levels in NAFLD patients：evidence from a gastro.2012.06.031.
randomized clinical trial［J］. J Gastrointestin Liver Dis，2018， ［56］WITJES J J，SMITS L P，PEKMEZ C T，et al. Donor fecal
27（1）：41-49. DOI：10.15403/jgld.2014.1121.271.kby. microbiota transplantation alters gut microbiota and metabolites in
［45］MOFIDI F，POUSTCHI H，YARI Z，et al. Synbiotic obese individuals with steatohepatitis［J］. Hepatol Commun，
supplementation in lean patients with non-alcoholic fatty liver 2020，4（11）：1578-1590. DOI：10.1002/hep4.1601.
disease：a pilot，randomised，double-blind，placebo- ［57］CRAVEN L，RAHMAN A，NAIR PARVATHY S，et al. Allogenic
controlled，clinical trial［J］. Br J Nutr，2017，117（5）：662- fecal microbiota transplantation in patients with nonalcoholic fatty
668. DOI：10.1017/S0007114517000204. liver disease improves abnormal small intestinal permeability：a
［46］SCORLETTI E，AFOLABI P R，MILES E A，et al. Synbiotics randomized control trial［J］. Am J Gastroenterol，2020，115（7）：
alter fecal microbiomes，but not liver fat or fibrosis， 1055-1065. DOI：10.14309/ajg.0000000000000661.
in a randomized trial of patients with nonalcoholic fatty liver ［58］KAJI K，TAKAYA H，SAIKAWA S，et al. Rifaximin ameliorates
disease［J］. Gastroenterology，2020，158（6）：1597-1610. hepatic encephalopathy and endotoxemia without affecting the gut
e7. DOI：10.1053/j.gastro.2020.01.031. microbiome diversity［J］. World J Gastroenterol，2017，23（47）：
［47］FEROLLA S M，COUTO C A，COSTA-SILVA L，et al. 8355-8366. DOI：10.3748/wjg.v23.i47.8355.
Beneficial effect of synbiotic supplementation on hepatic steatosis ［59］JIAN J，NIE M T，XIANG B Y，et al. Rifaximin ameliorates non-
and anthropometric parameters，but not on gut permeability in alcoholic steatohepatitis in mice through regulating gut microbiome-
a population with nonalcoholic steatohepatitis［J］. Nutrients， related bile acids［J］. Front Pharmacol，2022，13：841132.
2016，8（7）：397. DOI：10.3390/nu8070397. DOI：10.3389/fphar.2022.841132.
［48］VALLIANOU N，STRATIGOU T，CHRISTODOULATOS G S，et al. ［60］FUJINAGA Y，KAWARATANI H，KAYA D，et al. Effective
Probiotics，prebiotics，synbiotics，postbiotics，and obesity： combination therapy of angiotensin- Ⅱ receptor blocker and
current evidence，controversies，and perspectives［J］. Curr Obes rifaximin for hepatic fibrosis in rat model of nonalcoholic
Rep，2020，9（3）：179-192. DOI：10.1007/s13679-020- steatohepatitis［J］. Int J Mol Sci，2020，21（15）：E5589.
00379-w. DOI：10.3390/ijms21155589.
［49］VALLEJO-CORDOBA B，CASTRO-LÓPEZ C，GARCÍA H S， ［61］GANGARAPU V，INCE A T，BAYSAL B，et al. Efficacy
et al. Postbiotics and paraprobiotics：a review of current evidence of rifaximin on circulating endotoxins and cytokines in
and emerging trends［J］. Adv Food Nutr Res，2020，94：1-34. patients with nonalcoholic fatty liver disease［J］. Eur J
DOI：10.1016/bs.afnr.2020.06.001. Gastroenterol Hepatol，2015，27（7）：840-845. DOI：
［50］PELUZIO M D C G，MARTINEZ J A，MILAGRO F I. 10.1097/MEG.0000000000000348.
Postbiotics：metabolites and mechanisms involved in microbiota- ［62］COBBOLD J F L，ATKINSON S，MARCHESI J R，et al.
host interactions［J］. Trends Food Sci Technol，2021，108：11- Rifaximin in non-alcoholic steatohepatitis：an open-label pilot
26. DOI：10.1016/j.tifs.2020.12.004. study［J］. Hepatol Res，2018，48（1）：69-77. DOI：
［51］WANG S H，AHMADI S，NAGPAL R，et al. Lipoteichoic acid 10.1111/hepr.12904.
from the cell wall of a heat killed Lactobacillus paracasei D3-5 ［63］SUN D L，ZUO C，HUANG W，et al. Triclosan targeting of
ameliorates aging-related leaky gut，inflammation and improves gut microbiome ameliorates hepatic steatosis in high fat diet-fed
physical and cognitive functions：from C. elegans to mice［J］. mice［J］. J Antibiot （Tokyo），2022，75（6）：341-353.
Geroscience，2020，42（1）：333-352. DOI：10.1007/s11357- DOI：10.1038/s41429-022-00522-w.
019-00137-4. ［64］MAHANA D，TRENT C M，KURTZ Z D，et al. Antibiotic
［52］MA L Y，NI Y H，WANG Z，et al. Spermidine improves gut perturbation of the murine gut microbiome enhances the adiposity，
barrier integrity and gut microbiota function in diet-induced obese insulin resistance，and liver disease associated with high-fat
mice［J］. Gut Microbes，2020，12（1）：1-19. DOI： diet［J］. Genome Med，2016，8（1）：48. DOI：10.1186/
10.1080/19490976.2020.1832857. s13073-016-0297-9.
［53］中华医学会肠外肠内营养学分会，中国国际医疗保健促进交 ［65］GÓRSKI A，BOLLYKY P L，PRZYBYLSKI M，et al. Perspectives
流会加速康复外科分会，中国微生态治疗创新联盟，等 . 菌群 of phage therapy in non-bacterial infections［J］. Front Microbiol，
移植标准化方法学的建立与临床应用中国专家共识［J］. 中 2018，9：3306. DOI：10.3389/fmicb.2018.03306.
华胃肠外科杂志，2020，23（S1）：5-13. DOI：10.3760/cma. ［66］DUAN Y，LLORENTE C，LANG S，et al. Bacteriophage targeting
j.cn.441530-20200420-00231. of gut bacterium attenuates alcoholic liver disease［J］. Nature，
［54］ZHOU D，PAN Q，SHEN F，et al. Total fecal microbiota 2019，575（7783）：505-511. DOI：10.1038/s41586-019-
transplantation alleviates high-fat diet-induced steatohepatitis in 1742-x.
mice via beneficial regulation of gut microbiota［J］. Sci Rep， （收稿日期：2022-07-15；修回日期：2022-09-10）
2017，7（1）：1529. DOI：10.1038/s41598-017-01751-y. （本文编辑：贾萌萌）